Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial

IMPORTANCE: The 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol identified patients with recent (past 12 months) myocardial infarction (MI) as very high risk, in whom a PCSK9 inhibitor is reasonable to add to maximally tole...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Cardiol
Päätekijät: Gencer, Baris, Mach, François, Murphy, Sabina A., De Ferrari, Gaetano M., Huber, Kurt, Lewis, Basil S., Ferreira, Jorge, Kurtz, Christopher E., Wang, Huei, Honarpour, Narimon, Keech, Anthony C., Sever, Peter S., Pedersen, Terje R., Sabatine, Marc S., Giugliano, Robert P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2020
Aiheet:
Brief Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7240652/
https://ncbi.nlm.nih.gov/pubmed/32432684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.0882
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia